Icon

Harvoni - (90MG;400MG, 45MG;200MG)

Sofosbuvir, LEDIPASVIR None
90MG;400MG, 45MG;200MG
Less Than $1000 mn
None None
None None
None None
HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: • Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis • Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin • Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.
Yes
Harvoni Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17
*** *********

Harvoni - (33.75MG;150MG, 45MG;200MG)

Sofosbuvir, LEDIPASVIR None
33.75MG;150MG, 45MG;200MG
Less Than $1000 mn
None None
None None
None None
HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: • Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis • Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin • Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.
Yes
Harvoni Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.